Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Chromadex Corp CS (NQ: CDXC )

2.730 +0.020 (+0.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 277,067
Open 2.700
Bid (Size) 2.660 (15)
Ask (Size) 3.140 (1)
Prev. Close 2.710
Today's Range 2.665 - 2.770
52wk Range 1.250 - 4.650
Shares Outstanding 68,196,526
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen® (Patented Nicotinamide Riboside Chloride or NRC)
From ChromaDex Corporation
Via Business Wire
ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT)
From ChromaDex Corporation
Via Business Wire

Performance

YTD
+90.91%
+90.91%
1 Month
-16.00%
-16.00%
3 Month
-27.97%
-27.97%
6 Month
+86.99%
+86.99%
1 Year
+66.46%
+66.46%

More News

Read More
CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023
Via InvestorPlace
Earnings Preview For ChromaDex
Via Benzinga
Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Tuesday, June 11, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex’s Niagen® Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award
From ChromaDex Corporation
Via Business Wire
CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
ChromaDex Corporation Reports First Quarter 2024 Financial Results
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Nationwide Launch of Tru Niagen® at The Vitamin Shoppe®
From ChromaDex Corporation
Via Business Wire
ChromaDex’s NIAGEN® (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar® Cellular Nutrition Cellular Energy Supplement
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen® at Sprouts Farmers Market
From ChromaDex Corporation
Via Business Wire
ChromaDex Announces Tru Niagen® is Now Third-Party Verified Through the Alkemist Assured™ Transparency Program
From ChromaDex Corporation
Via Business Wire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results
From ChromaDex Corporation
Via Business Wire
ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024
From ChromaDex Corporation
Via Business Wire
Earnings Scheduled For March 6, 2024
Via Benzinga
ChromaDex to Participate in Renmark’s Virtual Non-Deal Roadshow on Monday, February 12, 2024
From ChromaDex Corporation
Via Business Wire
ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference
From ChromaDex Corporation
Via Business Wire
ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen®
From ChromaDex Corporation
Via Business Wire
A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen®, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD)
From ChromaDex Corporation
Via Business Wire
Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen®, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients
From ChromaDex Corporation
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.